Skip directly to content

ACRODAT® (Acromegaly Disease Activity Tool)

Even when achieving biochemical control, patients may still experience disease-specific symptoms such as soft tissue swelling, perspiration, and a generally reduced health status and quality of life.1,2,3 The patients’ own perspective of their health status may, therefore, be an important additional measure to assess the level of disease activity and for clinical decision making.

ACRODAT® is an interactive software medical device to assist adult endocrinologists in the holistic evaluation of disease activity in patients with acromegaly. The tool uses 5 parameters of patient information including: IGF-1, Tumour Status, Symptoms, Comorbidities and AcroQoL quality of life assessment to evaluate the patient’s disease status as stable, mild or severe.

ACRODAT® is a web-based medical device that has been developed, funded and provided by Pfizer Ltd. as a service to medicine to improve patient care in the United Kingdom.


Apply for ACRODAT® (Acromegaly Disease Activity Tool) - for UK HCP's only

To contact Pfizer for any other purpose, including adverse event reports, medical information requests, or data protection enquiries please call 01304 616161



  1. Lansang C, et al. Serum IGF-I in treated acromegaly – how normal is “normal”? Pituitary.2005;8:135-138.
  2. Neggers SJCMM, et al. Quality of life in acromegalic patients during long-term somatostatinanalog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93:3853-3859.
  3. Rubeck KZ, et al. Conventional and novel biomarkers of treatment outcome in patients withacromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur JEndocrinol. 2010;163:717-726.
PP-RDP-GBR-0126 / March 2019